Trial Profile
A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Generalized Anxiety Disorder.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 May 2017
Price :
$35
*
At a glance
- Drugs Duloxetine (Primary)
- Indications Generalised anxiety disorder
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly and Company
- 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 Sep 2012 Planned End Date changed from 1 Sep 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.